388 (75.9) 273 (74.0) 145 (78.4) 33 (68.8) ACPA positive, n (%) 374 (74.5) 276 (75.0) 153 (83.2) 29 (67.4)
Serious hepatic events
0.37 (0.08-1.07)
[3] 0 (0-5.57)
[0] 0 (0-5.57)
[0]
Serious stroke
0.39 (0.11-1.01)
[4]
1.39 (0.38-3.55)
1.22 (0.59-2.25)
[10] 0 (0.00-1.44)
[0] Serious myocardial infarction
0.39 (0.01-2.18)
[1] 0 (0-5.57)
[0] a Data are included from the DB and OL periods for all treatment arms; therefore, safety analyses for the TCZ-IV and TCZ-SC arms include all data from patients who received TCZ-IV and TCZ-SC, respectively, up to week 24 (n=631 for each arm) as well as those who remained on TCZ-IV and TCZ-SC during the OL period. b Data on injection-site reactions were not collected in the TCZ-IV group after week 24 as no SC injections were given. 
